SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Anika Therapeutics, Inc. (ANIK) has a negative trailing P/E of -19.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 68.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -5.02%, forward earnings yield 1.47%. PEG 0.52 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -19.9); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -5.02%).
- Forward P/E 68.0 — analysts expect a return to profitability with estimated EPS of $0.23 for FY2027.
- PEG Ratio 0.52 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -5.02% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 1.47% as earnings recover.
Overall SharesGrow Score: 29/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ANIK
Valuation Multiples
P/E (TTM)-19.9
Forward P/E68.0
PEG Ratio0.52
Forward PEG0.52
P/B Ratio1.51
P/S Ratio1.94
EV/EBITDA-45.4
Per Share Data
EPS (TTM)$-0.76
Forward EPS (Est.)$0.23
Book Value / Share$10.05
Revenue / Share$7.90
FCF / Share$0.31
Yields & Fair Value
Earnings Yield-5.02%
Forward Earnings Yield1.47%
Dividend Yield0.00%
SharesGrow IV$1,004.67 (+6466.5%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
22.1 |
2.84 |
3.23 |
6.95 |
- |
| 2017 |
24.7 |
-13.71 |
2.98 |
6.93 |
- |
| 2018 |
25.9 |
-0.64 |
1.84 |
4.60 |
- |
| 2019 |
26.9 |
0.56 |
2.54 |
6.39 |
- |
| 2020 |
-26.8 |
0.14 |
2.36 |
4.93 |
- |
| 2021 |
124.8 |
-1.07 |
1.80 |
3.49 |
- |
| 2022 |
-29.0 |
0.06 |
1.51 |
3.79 |
- |
| 2023 |
-4.0 |
-0.01 |
1.56 |
2.75 |
- |
| 2024 |
-4.3 |
0.13 |
1.57 |
2.02 |
- |
| 2025 |
-12.7 |
0.16 |
0.96 |
1.22 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.15 |
$103.38M |
$32.55M |
31.5% |
| 2017 |
$2.11 |
$113.42M |
$31.82M |
28.1% |
| 2018 |
$1.27 |
$105.56M |
$18.72M |
17.7% |
| 2019 |
$1.89 |
$114.61M |
$27.19M |
23.7% |
| 2020 |
$-1.69 |
$130.46M |
$-23.98M |
-18.4% |
| 2021 |
$0.28 |
$147.79M |
$4.13M |
2.8% |
| 2022 |
$-1.02 |
$156.24M |
$-14.86M |
-9.5% |
| 2023 |
$-5.64 |
$166.66M |
$-82.67M |
-49.6% |
| 2024 |
$-3.83 |
$119.91M |
$-56.39M |
-47% |
| 2025 |
$-0.76 |
$112.82M |
$-10.88M |
-9.6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.01 |
$-0.01 – $0.00 |
$117.22M |
$116.84M – $117.6M |
1 |
| 2027 |
$0.23 |
$0.22 – $0.23 |
$125.91M |
$124.22M – $127.6M |
1 |
| 2028 |
$0.52 |
$0.51 – $0.53 |
$132.62M |
$131.5M – $133.75M |
1 |
